2014 - Olof Johnell Science Award, International Osteoporosis Foundation
Jonathan D. Adachi mostly deals with Osteoporosis, Internal medicine, Surgery, Bone density and Physical therapy. His Osteoporosis research is multidisciplinary, incorporating perspectives in Placebo, Randomized controlled trial and Confidence interval. In his research, Parathyroid hormone is intimately related to Endocrinology, which falls under the overarching field of Internal medicine.
His Surgery research includes elements of Risedronic acid, Fracture risk, Femoral neck and Risk factor. His Bone density research also works with subjects such as
His primary scientific interests are in Osteoporosis, Internal medicine, Physical therapy, Surgery and Bone density. His studies deal with areas such as Orthopedic surgery and Placebo as well as Osteoporosis. The study of Internal medicine is intertwined with the study of Endocrinology in a number of ways.
He works mostly in the field of Physical therapy, limiting it down to concerns involving Randomized controlled trial and, occasionally, Meta-analysis, MEDLINE and Adverse effect. As part of one scientific family, Jonathan D. Adachi deals mainly with the area of Surgery, narrowing it down to issues related to the Confidence interval, and often Odds ratio. His Bone density research is multidisciplinary, incorporating elements of Relative risk, Prospective cohort study and Pediatrics.
Jonathan D. Adachi spends much of his time researching Osteoporosis, Internal medicine, Physical therapy, Randomized controlled trial and Hip fracture. His Osteoporosis research integrates issues from Orthopedic surgery, Incidence and Confidence interval. His study brings together the fields of Placebo and Internal medicine.
His work in Physical therapy addresses issues such as Intervention, which are connected to fields such as Home exercise. His biological study deals with issues like Psychological intervention, which deal with fields such as MEDLINE. His work is dedicated to discovering how Hip fracture, Cohort are connected with Osteoporotic fracture and other disciplines.
His scientific interests lie mostly in Osteoporosis, Internal medicine, MEDLINE, Physical therapy and Family medicine. His Osteoporosis research is multidisciplinary, relying on both Zoledronic acid and Confidence interval. His biological study spans a wide range of topics, including Randomized controlled trial, Gerontology and Scale.
His research investigates the connection between Family medicine and topics such as Systematic review that intersect with problems in Primary outcome and Observational study. His research in Hip fracture intersects with topics in Body mass index and Cohort. In his study, Incidence is inextricably linked to Surgery, which falls within the broad field of Glucocorticoid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles;Cathleen S. Colón-Emeric;Jay S. Magaziner;Jonathan D. Adachi.
The New England Journal of Medicine (2007)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
F. Cosman;D. B. Crittenden;J. D. Adachi;N. Binkley.
The New England Journal of Medicine (2016)
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
J D Adachi;W G Bensen;J Brown;D Hanley.
The New England Journal of Medicine (1997)
Canadian normative data for the SF-36 health survey
Wilma M. Hopman;Tanveer Towheed;Tassos Anastassiades;Alan Tenenhouse.
Canadian Medical Association Journal (2000)
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
Pierre D. Delmas;Kristine E. Ensrud;Jonathan D. Adachi;Kristine D. Harper.
The Journal of Clinical Endocrinology and Metabolism (2002)
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Jonathan D. Adachi;Kenneth G. Saag;Pierre D. Delmas;Uri A. Liberman.
Arthritis & Rheumatism (2001)
Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Ann Cranney;Peter Tugwell;George Wells;Andrew Willan.
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
S Lekamwasam;J D Adachi;D Agnusdei;J Bilezikian.
Osteoporosis International (2012)
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
P.D Delmas;H.K Genant;G.G Crans;J.L Stock.
II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women
Ann Cranney;George Wells;Andrew Willan;Lauren Griffith.
Endocrine Reviews (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: